Striking the right balance between protection competition law and intellectual property rights is of utmost importance, especially in the pharmaceutical sector; affordable generic drugs are as important as new innovative drugs. Pay for delay settlements take place at exactly this intersection. They end patent infringement litigation but, at the same time, delay entry of generic drugs by means of a substantial payment from the brand company to the generic. Whereas, the US Supreme Court opted for a rule of reason approach which requires an analysis of the potential anticompetitive effects, the European Commission regarded such settlements as restriction by object, finding an infringement without the need for an effects-based analysis. This approach is criticised and a novel "structured effects-based" approach is proposed allowing the authority to effectively scrutinise such settlements while striking the right balance in order to protect the innovative process and the exercise of intellectual property rights.
Introduction
Pay for delay settlements in the pharmaceutical sector are currently at the centre of attention of European competition law and policy. A pay for delay settlement is an arrangement between an innovating pharmaceutical company (brand company) and a generic pharmaceutical company (generic company), whereby the generic company agrees not to enter the market in return for a substantial payment from the brand company. This is often exceeds the profits the generic company would have made by entering the market. In other words, the brand company pays the generic company to stay off the market. On the one hand, this delay of entry based on the substantial payment from the brand company to the generic company is a major concern with regard to competition law and policy, as the conduct has the potential to foreclose the market for a certain drug and cause significant consumer harm.
Originating from the United States, these settlements have therefore received extensive antitrust scrutiny. The Federal Trade Commission has in fact estimated that pay for delay settlements have delayed generic entry by an average of 17 months at a cost to the consumer of savings totalling US$ 3.5 billion for the period of 2004 to 2009; 1 also affecting the affordability of potentially life-saving drugs.
One the other hand, one has to remember that pay for delay settlements are patent settlements and that such settlements are generally regarded as a legitimate means to end patent infringement litigation. The brand company has obtained 20 years of patent protection as a reward for its innovation and patent policy permits the brand company to actively exclude other companies from using its innovation, which naturally includes defending its patents against infringement. Unduly intervention and ultimately restriction of the granted intellectual property right might stifle innovation which might lead to fewer innovative drugs in the long-run.
Although the existence of the intellectual property right should generally not get affected by competition law, its exercise and the exploitation of the intellectual property right in question that can be subject to competition law scrutiny. 2 Keeping both policy consideration in mind it is paramount to strike the right balance between the aims of competition policy in the pharmaceutical sector and brand company's right to defend its patents by means of patent infringement litigation and patent settlement. The aim has to be to ensure the maximum generic competition possible to ensure the affordability of drugs without jeopardising the innovative process leading to new drugs.
In the United States, following long and extensive scrutiny of pay for delay settlements by the US Federal Trade Commission (FTC), the US Supreme Court has finally addressed this balance its judgement in FTC v. Actavis on 17 June 2013. 3 In this judgment the US Court adopted a "rule of reason" approach requiring to show the anticompetitive effects of a pay for delay settlement.
Just two days later, the European Commission handed down its very first decision to a pay for delay arrangement, imposing a fine on a brand company, Lundbeck, and a number of generic companies for delaying the market entry of a cheaper generic version of citalopram, an antidepressant drug, finding this conduct to be an anticompetitive agreement and thus an infringement of Art. 101 TFEU. 4 The total of the fine imposed was in excess of €152 million.
In subsequent decisions, the Commission imposed a fine of €16 million on Johnson & Johnson and Novartis for the delay of a generic pain-killer based on Fentanyl 5 , and a fine in excess of €427 million on Servier and five generic companies in relation to the delay of generic version of the blood pressure drug Perindopril in July 2014. 6 In the case of Lundbeck, the parties have since appealed the decision to the General Court. 7 Since these appeals, it has become evident that the European Commission has found the pay for delay settlement in Lundbeck to be a restriction by object, meaning that it treats the arrangement as an infringement, regardless of whether it actually has an anticompetitive effect. This is a lot less onerous on the authority than treating the arrangements as restrictions by effect, which requires it to establish actual anticompetitive effects. The European Commission therefore seems to have struck the balance between the competition policy and protection of the brand company's right to defend its patent far more in favour of competition law intervention than the US Supreme
Court in FTC v Actavis.
This approach by the European Commission is criticised by this article. Yet, at the same time, this article also offers a solution to the problem, adjusting the balance without impairing the European Commission in its enforcement efforts in relation to pay for delay settlements that have anticompetitive effects.
Contrary to the belief in the lead up to the decision that the European Commission is only likely to be successful in its enforcement efforts when relying on a restriction by object, 8 this article not just rejects this approach but proposes a novel "structured effects-based" test for an investigation of pay for delay settlements, which is inspired by the recent US Supreme Court judgment in FTC v Actavis. 9 Following a cautious analysis of the rationale behind the US Supreme Court's judgment -taking into consideration the regulatory differences between the US and Europe -a novel structured effects-based analysis is proposed. The analysis of the FTC v. Actavis judgment and adapting it to the European framework is not just motivated by 5 It should thus not be too far-fetched to consider the rationale behind the US Supreme Court's judgment in Actavis for the analysis of pay for delay settlements in the European context. This not only ensures that the approach of the European Commission is not overly restrictive, but also strikes the right balance with regard to the protection of the innovative process and the exercise of intellectual property rights.
This article is structured as follows. First, the regulatory differences between the US and the European pharmaceutical sector which need to be considered for the adaption of the US Actavis judgment to the European regulatory framework. It then examines the possible prevention or distortion of competition through pay for delay settlements. The notion that such settlements should be scrutinised as restrictions by object is rejected. The effects-based analysis then discusses and considers the US Supreme Court's judgment in Actavis, including the FTC's amicus curiae brief in Effexor XR, as possible sources of guidance. Following this discussion, a novel "structured effects-based" approach to pay for delay settlements is developed, which acknowledges the general need for patent settlements and, as such, is not considered to be over-inclusive. Finally, the article concludes providing policy recommendations for future investigations. Although the above described pay for delay scenario should already raise concern, the potential for anticompetitive foreclosure by means of pay for delay settlements is heavily dependent on the pharmaceutical regulatory framework in place. It is therefore necessary to examine the differences between the US and European pharmaceutical regulations, before one can determine to what extent the rationale behind the US Supreme Court's approach to pay for delay settlements can be adopted in Europe.
Regulatory differences between the US and Europe

The United States and the Hatch Waxman Act
In the United States the pharmaceutical sector is regulated by the so-called Hatch Waxman Act. 11 The purpose of this act is to incentivise generic companies to enter the market for a given drug prior to the brand company's patent expiry by challenging the validity of the brand company's patent. In theory this should ensure that only brand drugs based on valid patents benefit from the maximum patent protection. This challenge of brand patents by a generic company that intends to enter the market generally triggers patent infringement litigation between the two parties. In the context of this patent infringement litigation most of the pay for delay settlements take place.
According to the regulatory framework of the Hatch Waxman Act, the generic applicant can apply to the US Food and Drug Administration (FDA) for drug approval prior to the expiry of the brand company's patents but must notify the brand company whose drug it wants to market as a generic version about the application. The so-called 'Paragraph IV certification' has to mention every related patent that has been previously filed by the brand company in the FDA's so-called Orange Book, a register of all patents in relation to every brand drug that is registered with the FDA . This gives the brand company the ability to challenge the generic application on grounds of patent infringement. 12 The requirement for the FDA to consider the listed patents in the Orange Book therefore creates a so-called patent linkage. If the brand company decides to challenge the generic application, the FDA's decision on the generic approval is postponed by 30 months to enable the parties to resolve their patent dispute in court. Following this postponement, the FDA approval of the generic drug will be effective from the date on which: (1) the patent expires, (2) the court reaches a 11 [XXX] 12 C. S Hemphill and Mark A Lemley, 'Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act' (2011) 77 ANTITRUST LAW JOURNAL 947. 952. decision on the non-infringement or patent invalidity in the patent litigation, or (3) the 30 months from the date of notification have expired, 13 whichever comes first. 14 Under normal circumstances, the court's judgment should have either declared the patent invalid, enabling generic applicants to enter the market because they no longer have to obey this patent, or declared that the patent had not been infringed by the generic applicant leading to the start a period of 180 days of generic exclusivity. This exclusivity period was introduced by the Hatch Waxman Act with the intention to provide the first generic applicant with an incentive to incur the risk of patent infringement litigation and the costs that are associated with it. 15 During this period of generic exclusivity, the FDA is not allowed to grant any further generic drug applications. After this period, as many generic companies as are willing to enter the market may do so simultaneously.
Pay for delay settlements are, however, able to skew these incentives in favour of the parties to the settlement and to the disadvantage of the final consumer. As mentioned above, the 30-month stay triggered by the FDA's approval decision of the generic application for market authorisation should allow the parties to litigate the patent infringement. Instead, the parties settle their patent infringement dispute. The generic company is nonetheless granted the 180 days of generic exclusivity, as the generic exclusivity is linked to the filing of the first generic drug approval application with the FDA and not to successful litigation. 16 Because the initial patent infringement lawsuit has not been concluded by means of a judgment, but rather by means of settlement, the start of the 180 day exclusivity period is set to the date of actual generic entry, which has been stipulated by the parties in the settlement agreement. In doing so, the parties can control and delay subsequent generic entry, as the FDA is not allowed to grant further generic drug approvals until the 180 generic exclusivity has elapsed. If the generic applicant agreed not to enter the market until 180 days prior to patent expiry, the brand company's patent monopoly is effectively unchallengeable for the entire duration of the patent life, as the generic exclusivity functions as a regulatory 13 Federal Trade Commission, Generic drug entry prior to patent expiration: A FTC study (2002 bottleneck. 17 In return for this delayed entry of the first-filing generic company, the brand company typically compensates the generic applicant with a payment that is ideally larger than the estimated profits of the generic company.
In terms of patent law, this effect could be described as turning the rebuttable presumption of validity into effectively a non-rebuttable presumption, allowing the brand company to obtain a guaranteed legal patent monopoly. However, receiving a patent is not equivalent to an entitlement to exclude every competitor. The patent holder can only try to exclude its competitors and the probability of success is based on the strength of the patent itself. 18 In 2003 forfeiture rules were introduced to the Hatch Waxman Act which now allow subsequent generic competitors to overcome this bottleneck, yet the process is still very lengthy, causing considerable delays. This forfeiture forces the first generic applicant to start using its generic exclusivity or risk losing it, if a later-filing generic applicant wins its own patent lawsuit. However, the lawsuit has to be won in front of an appellate court. 19 If this is the case, the first generic applicant has to start using its generic exclusivity within 75 days. 20 So, in order to overcome this regulatory bottleneck the generic company would have to file an ANDA application, win a patent lawsuit, win the appeal of this patent lawsuit, wait 75 days for the first-filing generic company to start using its generic exclusivity and then wait another 180 days until it can enter the market. This process can easily endure for several years and therefore can delay subsequent generic by a significant amount.
In conclusion, a brand company can use a pay for delay settlement to foreclose the market itself until the generic exclusivity of the generic company that has entered into the agreement has expired. It also shields it patents from being challenged by any potential competitor, thereby guaranteeing a legal monopoly. This outcome that might be within the technical boundaries of patent rights but, at the same time, contradicts fundamental patent policy. The patent settlement itself is not based on the validity of the patent and the probability of success of getting the validity confirmed by a court's judgment. Rather, it is 17 Hemphill and Lemley (n 13) 963. 18 Carl Shapiro, 'Antitrust limits and patent settlements ' (2003) based on a payment by the brand company to the generic company which reflects, at least the estimated profit of the generic company if it were to have entered the market.
Europe
In contrast to the US regulatory framework of the Hatch Waxman Act, the European regulatory framework lacks most of the "US factors" that facilitate market foreclosure. Firstly, the European drug safety regulators that approve brand and generic drugs and grant market authorisations do not take economic factors into consideration, such as patent rights of the 
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This approach to pharmaceutical regulation in Europe is not only reflected in further secondary legislation 22 but also in the European Commission's pharmaceutical sector inquiry where it was found that no other criteria apart from those regarding public health -such as the safety, the quality, and the efficacy of the relevant drug -should be taken into consideration when deciding upon the application for a market authorisation. 23 If it should be the case, that a market authorisation for a generic version of a drug interferes with the patent status of the originator drug, the issue should be resolved by means of private patent litigation in front of competent courts. The patent protection for a drug is an important issue for the pharmaceutical company, but is dealt with separately from the safety and efficacy of the drug. lengthy application procedure as the brand company but can rely on an abbreviated application procedure. 24 However, there is no difference between the first filing applicant and any subsequent generic company that decides to enter the market prior to patent expiry. Due to the missing patent linkage, the European framework has not created a bottleneck similar to the FDA. The relevant agency is not prevented from approving several generic drugs prior to patent expiry. Yet every generic entrant runs the same risk of being sued for patent infringement by the brand company which might occur separately to the approval process.
For this reason, it is also not necessary to incentivise the first filing generic applicant with a period of generic exclusivity, as this applicant is not the only party that can challenge the validity of the brand company's patents that cover the drug in question. As a result the European drug approval regulation does not automatically create a type of temporary duopoly without potential for further entry within the market for a specific drug simply by granting the first market authorisation.
As a consequence, it is only possible for the brand company to secure duopoly profits for a certain period of time, in return for payment to the first generic entrant, if the number of possible generic entrants is very limited. For example, if only one of the potential generic entrants has the necessary financial power to take the risk of being sued for patent infringement, it would be a viable option to pay off this competitor.
However, if several potential competitors are equally strong or equally willing to take the risk of possible patent infringement litigation, the viable options for the brand company to achieve market foreclosure become more complex. Although it has been suggested that paying off multiple entrants at the same time might even be cheaper than paying off just one competitor due to the price development of the drug in question after the market entry of multiple generic versions of the drug, 25 generic companies should have an incentive to disguise their intent to enter to the last minute and therefore enter sequentially instead of simultaneous. This would force the brand company to enter into agreements with each of the generic entrants in turn, which would increase the brand company's cost for market foreclosure significantly. The incentive for the brand company is to retain its monopoly for a certain drug, despite sharing the profits with the first generic entrant who has agreed not to enter the market. A subsequent generic entrant is therefore still likely to have the same incentive to enter the market as the first generic entrant -to gain its share of the monopoly. However, every paid of potential generic entrant brings the brand company one step closer to market foreclosure. Thus the brand company's payment to the generic competitor to achieve foreclosure should increase with every further generic company being paid off, with the last potential generic entrant being the most expensive to be paid off.
However, a pay for delay settlement could be a viable option to foreclose the market, if the market in question is less diverse than anticipated. If this should be the case, the actual structure of the relevant pharmaceutical market could prove an influential factor when deciding whether or not to enter into a pay for delay settlement, in addition to factors relating to market value and the national pharmaceutical regulations of the Member State in question.
Fundamentally, the fewer generic companies are able to enter the market, the more likely foreclosure of the market by the incumbent becomes. If only a few generic companies are capable of entering "at their own risk" prior to patent expiry despite a large number of generic companies being present in the pharmaceutical sector as a whole. In fact, this might be the case in the European Commission's proceedings against the French pharmaceutical company Servier and its recent decision against Lundbeck. 26 The Commission has sent a statement of objections to Servier and a number of generic companies taking the view that 'patent settlement agreements between Servier and the generic companies were aimed at delaying or preventing the market entry of cheap generic versions of perindopril'. 27 In Lundbeck the European Commission has imposed a €152 Million fine on Lundbeck and a small number of generic companies because of the delay of generic entry of citalopram. 28 Keeping these important differences between the two regulatory frameworks and their impact of the potential for anticompetitive foreclosure in mind, this article turns now to the discussion whether European pay for delay settlements should be regarded as restrictions by object or rather effect.
Pay for delay as restriction by object
Under European competition law, Art. 101(1) TFEU is only infringed if the agreement has as its 'object or effect the prevention, restriction or distortion of competition within the internal market'. Indeed, the question of whether a pay for delay settlement is to be regarded as an infringement by object or by effect is one of the core issues to determine. These two are alternative requirements and should be read disjunctively. 29 The answer to this question determines the level of proof that the European Commission needs to satisfy in order to find an infringement. Agreements that are a restriction by object always fall within the scope of Although an agreement can be restrictive by object, even if its object is not solely anticompetitive but also serves legitimate aims, 32 it is according to the Court of Justice now settled case law that 'regard must be had inter alia to the content of its provisions, the objectives it seeks to attain and the economic and legal context of which it forms a part'. 33 If these factors are considered, it is sufficient to show that the conduct in question is merely capable of resulting in the prevention, restriction, or distortion of competition within the relevant market. 34 Furthermore, there is no requirement to consider whether the potential negative effect on competition will deprive the final consumer of competitive advantages in terms of supply and price. 35 Where an agreement is found not to be a restriction by object, the European Commission has to conduct an extensive analysis of the restrictions by effect on the market, which is a much more onerous task. 36 The effects need to be established in the context of factual and legal circumstances which cause it to prevent, restrict or distort competition. 37 With regard to pay for delay settlements, it has been argued that such settlements should be regarded as restrictions by effect and not by object, as they are by their very nature settlements of patent litigation. 38 It is generally accepted that settlements are a legitimate means by which to end disputes, especially in patent litigation which is costly and timeconsuming. 39 Further consideration has been given to the fact that the settlements concern patents which constitute exclusive rights that entitle the holder to exclude infringing products.
It would therefore be difficult to categorise such settlements as restrictions by object. 40 Furthermore, a large number of settlements identified in the pharmaceutical sector inquiry were found not to restrict generic entry into the market; some even had procompetitive features, 41 and only a minority gave rise to competition concerns. 42 43 However, in spite of the abovementioned consideration and the European Commission's quoted statement from its final report of the pharmaceutical sector inquiry -suggesting the application of an effects-based analysis -does not guarantee that the Commission is not opting for a "by object" analysis after all. Despite having proclaimed the more effects-based approach to Art. 101 TFEU for more than a decade in its regulations and guidelines, 44 the European Commission has framed 17 out of 18 infringement decisions since January 2000 in "object" terms. 45 The underlying reason for this kind of approach is likely to be based on strategic considerations, as it is a lot easier to bring a successful case when there is no requirement to show the anticompetitive effects of an agreement. The European Commission regularly justifies this approach by stating that an "object" restriction should not be seen as a "per se" style infringement as in the United States. Even an "object" restriction would allow for justifications which make the presumption a rebuttable one. Yet it has been correctly stated that such an argument is only valid if a rebuttal is a 'reality rather than a theoretical possibility'. 46 In fact, the European Commission did revert to this modus operandi in its Lundbeck decision -the first European decision in relation to pay for delay settlements. This became apparent on 9 November 2013, when a number of generic companies and Lundbeck itself appealed the decision to the General Court, arguing that the European Commission had committed a manifest error of assessment by finding that the pay for delay settlement constituted a restriction of competition 'by object'. 48 Earlier this year, the European Commission then published its Lundbeck decision. With regard to its finding of a restriction by object the European Commission started by citing extensively the recent Allianz Hungaria judgment including the reference to the T-mobile judgment where the Court held that 'in order for the agreement to be regarded as having an anti-competitive object, it is sufficient that it has the potential to have a negative impact on competition '. 49 This finding arguably set a lower standard for restriction by object as it no longer referred to the 'sufficient' harm to competition but the mere potential to have a negative effect and has already lead at the time of the decision to the criticism and anxiety concerning the creation a too broad category of restriction by object. In addition, the European Commission also relied on the General Court's judgment in Groupement des Cartes Bancaires where is was held that the restriction to competition must be serious yet not obvious. 50 Although the statement referred to the legal and economic context that needs to be considered in the analysis, it arguably broadens the scope of restrictions by object. Interestingly, the European Commission did not, at least explicitly in the decision, put forward the argument that Lundbeck's conduct was outside the scope of competition on the merits by using the settlements as a means to game the regulatory system This leads to an additional factor that needs careful consideration. Regarding pay for delay settlements in Europe as restrictions by object also increases the potential for Type I errors and over-enforcement, due to the novel nature of the competition law infringement.
Depending on the actual definition of pay for delay settlements, patent settlements with a value transfer from the brand company to the generic company which are followed by the exit of the generic company from the market could fall foul of Art 101(1) TFEU. Such a payment could, however, be perfectly reasonable. It might settle litigation costs or may constitute a payment for services rendered by the generic company. 56 An indicator for anticompetitive conduct could be the level of the payment. However, such an evaluation cannot take place for object restrictions. The different factors that need to be taken into account are too manifold to regard such conduct as a restriction by object without any experience. Based on the novelty of the infringement and the associated inexperience one should also reject a potential countervailing argument that the level of analysis in the object category has been raised by the ECJ in recent judgments, suggesting a market structure 55 [XXX] 56 [XXX] inquiry in the context of object cases. 57 Such an analysis of market structure would assist in determining the actual anticompetitive potential of the pay for delay settlement, as mentioned above, but it would not account for any potential justification of the value transfer from the brand company to the generic, failing to deal with the propensity to overenforcement and the creation of false positives. This issue and more generally the capacity building of enforcement experience in the area can only be achieved through an effects-based analysis.
Two exceptions to this general rule could nonetheless be considered. One is the case when the agreement clearly exceeds the scope of the patent; for example, when the agreement prevents the generic company from entering the market after the protection of the relevant patent has elapsed. This type of conduct has also been accepted as being anticompetitive by the US jurisprudence prior to the US Supreme Court's decision in Acatvis. 58 The second exception could be a situation in which the parties are aware of facts that would remove the uncertainty regarding the outcome of patent litigation to the point at which the European Commission would no longer have to second-guess the validity of the patent at issue. One possibility could be the discovery of internal documents that provide evidence that the patentee was aware of patent's invalidity. 59 In such a scenario would not have to rely on any past experience in relation to the anticompetitive effects, as the anticompetitive purpose and the very nature of the agreement becomes apparent, which justifies the finding of an restriction by object. Apart from these noted exceptions, pay for delay settlements should not be subjected to a "restriction by object" analysis. These considerations and arguments are not unique to the European context. The very same issues had to be addressed by the US Supreme Court in its Actavis judgment. The following subsection therefore discusses the US judgment itself in order to establish whether inspiration can be drawn from Supreme Court's analysis.
Pay for delay as restriction by effect
FTC v Actavis and the FTC's amicus curiae brief in Effexor XR
This section discusses the recent US Supreme Court decision in Actavis and the Federal Trade
Commission's (FTC) amicus curiae brief in Effexor XR, in which the FTC argues that the Actavis rule should be extended to non-cash payments as a form of value transfer. Drawing conclusions from the judgment and the amicus curiae brief might help to develop a European approach to pay for delay settlements.
In Actavis, the US Supreme Court for the first time examined the legality of pay for delay settlements. The FTC had applied for writ of certiorari, the petition for judicial review by the US Supreme Court, in earlier pay for delay settlement cases but the US Supreme Court 63 (n 32 The finding that pay for delay settlements should be immune from antitrust liability was based on the assumption that such liability would undermine the patent incentive and would stifle innovation. 73 Additionally, the courts stressed the general importance of the settlements, especially in patent infringement litigation. 74 The only noted exception under which the court has to consider the patent's validity in an antitrust analysis is in the case of fraud in front of the patent office or in the case of sham litigation. In the event of such conduct, the agreement's restrictive effect on competition would be regarded as beyond the exclusionary scope of the patent. 75 The Third Circuit expressly rejected the "scope of the patent" test, holding pay for delay settlements to be a prima facie unreasonable restraint of trade. The Court based this finding on a number of reasons. First of all, it rejected the notion that the statutory presumption of validity in patent law is a substantive right of the patent holder; rather, it constitutes a procedural device that puts the burden of proof on the party that is challenging patent validity. 76 Furthermore, pay for delay settlement cases do not concern patent validity but rather patent infringement, in which case the burden of proof is on the patent holder -hence, the argument based on the presumption of validity is misguided. 77 Secondly, the Court emphasises that
''the public interest […] is dominant in the patent system and […] the right to challenge [a patent] is not only a private right to the individual, but it is founded on public policy. 78
This public policy consideration on which not only vital for a efficient patent system but also with regard to the Hatch Waxman Act, which is aimed at providing incentives to increase competition in the pharmaceutical sector through patent challenges by generic companies.
The Court directly quoted congressional statements made in relation to the Bill which underlines the intention of Congress to provide consumers with cheaper generics by encouraging generic companies to challenge patents that they regard as weak or invalid. 79 This public policy consideration is undermined by the "scope of the patent" test. 80 Applying these findings to the case at hand, the Court decided that the criteria for a "quick A firm without such power would not be likely to pay 'large sums to induce others to stay of the market'. 92 This finding is based on the rationale that, in a competitive market, the incentive of keeping a competitor out of the market should be close to zero. In a highly competitive market, price-cost margins are very low and this situation cannot be improved by keeping competitors out of the market. 93 However, this incentive rises with the increase in price-cost margins. A firm with market power typically enjoys high profit margins and therefore has an incentive to defend these by excluding competitors from the market. 94 In the case of a time-limited monopoly, such as patents, the rational patentee would pay no more than the anticipated monopoly return over the remaining period of patent protection. 95 Thus the level of market power is a function of the size of the payment made to the generic -
The bigger the size of the payment, the higher the market power.
Furthermore, the Court also noted that the size of the payment can also be an indicator for the anticompetitive harm caused by the pay for delay settlement and can act as 'a workable surrogate for a patent's weakness'. 96 According to the Court, it was therefore also unnecessary to evaluate the validity of the patent itself as part of the rule of reason analysis.
It agreed with the FTC that the rationale behind a payment of this size cannot in every case be traditional settlement considerations. 97 It should rather be seen as evidence that the patentee is not confident in the strength of the patent in question and seriously doubts that it would prevail in patent litigation. 98 According to the Court, a settlement in such a situation reduces the extent or likelihood of competition. The Court also indicated that a small reduction of likely competition is sufficient by stating that:
' Nonetheless, the Court conceded that payments might reflect legitimate settlement considerations, such as avoiding litigation costs or attaining fair value for services provided.
Yet this possibility should not prevent the FTC from scrutinising the settlement. Ultimately, a district court should be able to examine the size of the payment, its likely anticompetitive effects and its potential justifications in the future. 100
Judging by these considerations, it is possible to set out the following test to determine whether a pay for delay settlement restricts competition: 101
(1) The plaintiff has to prove that the relevant payment to the generic company is large by:
a. Valuing the consideration flowing from the patentee to the alleged infringer, and b. Deducting the avoided litigation costs for the patentee.
If this net payment is positive it may be understood as a prima facie restriction of competition by means of delaying entry.
(2) The defendant then has the burden of proof for showing that this net payment can be explained as payment for services or goods rendered by the alleged infringer to the patentee as part of the same transaction.
In the wake of the US Supreme Court's judgment in Actavis, the Federal Trade Commission has now sought to extend the Actavis rule to non-cash payments. In recent months, the FTC has filed two amicus curiae briefs; one in the District Court for the district of New Jersey, 102 and one in the District Court for the eastern district of Pennsylvania. 103 Both cases concern patent settlements between a brand company and a first-filing generic company that do not involve pay for delays in monetary terms but rather in terms of non-cash contributions for the generic company. The respective brand companies agreed as part of the settlement not to launch an authorised generic version of the brand drug during the period of generic In the light of this argument the FTC proposes in its briefs as amicus curiae to extend the Actavis rule to non-cash payment by asking:
(1) Whether the alleged payment is something that a generic challenger could not have obtained had it won the litigation, and (2) Whether the parties are sharing monopoly profits preserved by avoiding competition. 108 A "no-authorized-generic commitment" is a benefit that a generic company could not obtain by prevailing in patent litigation. Even if the generic company were to win the patent litigation, the brand company would nonetheless have the right to compete against the generic company by entering the market with an authorised generic, as patent invalidity or noninfringement does not affect the right to market an FDA-approved drug. 109 This extension of the judgment in Actavis seems to be sensible. Although this judgment only refers to state antitrust law it is likely to have a signalling effect for the federal circuit and "nudge" federal district court in a similar direction.
Application of the rationale in FTC v Actavis in the European context
Following the discussion of the majority opinion of the US Supreme Court, the question is whether the issues surrounding patent validity, including the pre-judging of patent courts, could also be avoided in the European context by applying the rationale of the US Court. As set out above, the Supreme Court infers not only market power but also the anticompetitive effect from the size of the payment that is directed from the brand company to the generic company and, therefore, it avoids an assessment of the validity of the patent in question.
Taking the same approach with regard to market power in the European context should not be problematic. Market power as a concept is defined as the ability to profitably raise prices to a supra-competitive level, to profitably maintain output in terms of product quantities, product quality and variety, or to innovate below competitive levels for a period of time. 112 Similarly to the situation in the United States, the brand company should only be willing to make a payment to the generic company that exceeds litigation costs and costs for services rendered, if the brand company's intention is to protect its high price-cost margins.
However, such high price-cost margins are only likely to occur in markets that are not competitive. It should therefore be possible, by implication, to infer market power through the willingness to defend high price-cost margins by way of assessing the size of the payment.
However, inferring anticompetitive effects from the size of the payment is more problematic in the European context and must therefore be discussed in detail. It is important to consider the regulatory context in which pay for delay settlements take place on both sides of the Atlantic and factor in the regulatory differences. In the United States, the relevant market can be effectively foreclosed by a single pay for delay settlement. The brand company induces the first generic entrant by means of a substantial payment not to market its generic drug for a certain amount of time, thereby postponing the period of generic exclusivity which is, in turn, the trigger for subsequent generic applications to the FDA. In light of this regulatory bottleneck, it is acceptable to infer anticompetitive effects from the size of the payment, due to the causal link between the size of the payment from the brand company to the generic company and the delay of generic entry which leads to the foreclosure of the market.
However, such a regulatory bottleneck does not exist in the European context. Ultimately, this also means that one cannot presume that an anticompetitive foreclosing effect results from the agreement between the brand company and a single generic company that agrees not to enter the market or to delay its entry. It is therefore also not appropriate to infer an anticompetitive effect solely on the basis of the size of the payment within this agreement, just as in the United States.
That said, this should also not lead to the conclusion that the anticompetitive effects of pay for delay settlements in Europe can only be shown by means of examining the validity of the patent. The assessment of the regulatory framework in Europe does not suggest that it is impossible for a single pay for delay settlement to result in anticompetitive foreclosure effects. The lack of a regulatory bottleneck similar to the Hatch Waxman Act should not be equated with a lack of potential for anticompetitive foreclosure in Europe. The manifestation of such an effect is, rather, dependent on the actual market structure and the competitive environment in the relevant market. Imagine a scenario where a number of generic companies are present in a given market, but only one of these companies has the financial and technical means to realise the economies of scale that are necessary to profitably market the generic version of a branded drug. In this case, the remaining generic companies would not be able to enter the market to exert competitive pressure on the brand company despite the lack of any legal or regulatory absolute barriers to entry and the ability to apply for market authorisation. In effect, this scenario would lead to at least the same level of anticompetitive effects witnessed in the United States. Indeed, the situation could be even more detrimental to competition due to the lack of potential competitors which are foreclosed by the agreement.
It should therefore be possible to infer anticompetitive foreclosure effects from the size of the payment in addition to an assessment of the competitive environment within the relevant market (ie the number of potential generic competitors).
Such an analysis would not be dissimilar to the ECJ's judgment in Delimitis v Henninger Bräu, 113 which epitomises the EU Court's approach to restrictions by effect. In this case, the Court had to assess whether exclusive beer supply agreements between a brewery and public houses amounted to a restriction by effect because of their potential to foreclose the market.
Having highlighted the general pro-competitive features of such beer supply agreements, 114 the Court set out a test to establish whether the beer supply agreement in question led to an anticompetitive foreclosure of the relevant market. In order to establish the potential foreclosure, the Court deemed it necessary to define the relevant market. The Court then went on to examine whether it was difficult for competitors to gain access to the market in the light of the economic and legal context of the agreement at issue. 115 The market in The proposed test is the following:
(1) The European Commission has to define the relevant market and examine the competitive environment within the market.
(2) The European Commission must also prove that the relevant value transfer to the generic company is large either: This test is not over-inclusive; it takes into consideration the efficiency considerations of patent settlements and the actual conditions on the relevant market. It does not disincentivise patent settlements and does not condemn settlements that have no appreciable anticompetitive effect on the market. Even if the two parties enter into a pay for delay settlement that included a positive net payment, the agreement is not likely to produce anticompetitive effects if a number of equally efficient generic competitors are able to enter the market -hence the need to cumulatively satisfy the criteria under (2)(a) in order to infer anticompetitive effects from the positive net payment. The test is also not over-burdening the parties involved as it is assumed that the parties have the best knowledge of the competitive environment within the relevant market and are therefore well-equipped to determine whether the agreement in question is likely to have a foreclosing effect on the market. Furthermore, the test can also be applied to a situation where the brand company enters into pay for delay settlements with a number of generic companies in order to foreclose the market.
It is not suggested that the proposed test, and more precisely the evidentiary burden of the European Commission to quantify the value considerations from the brand company to the generic company, is straightforward to satisfy. Quantifying the cost of litigation is only one aspect. Although it might sound more challenging to put a "price tag" on an exclusive licence that is granted as part of a side deal for other services rendered in relation to drug distribution or the provision of back-up manufacturing capacity, its complexity has been downplayed given that these services are routinely sold in a broad market. 120 The European
Commission should therefore have a number of reference points in the market. The alternative to the quantification of the value transfer would be an investigation into the validity of the underlying patent, which is not only more onerous but also more problematic for the European Commission. This is due to the fact that the assessment of patent validity by a competition authority leads to the "second-guessing" of patent authorities and the potential judgment of a patent court. Such a judgment is not, however, a quantitative exercise but rather a subjective value judgment with regard to the relevant prior art of the patent and its "non-obviousness" or "inventive step". Judges in one jurisdiction might hand down a judgment that contradicts judgments regarding the same patent in another jurisdiction. Thus, it is regarded as a lot more sensible and much less onerous for the competition authority to undertake the quantitative exercise to evaluate the consideration flowing from the brand company to the generic company than delving into the subjective assessment of patent validity.
Conclusion
A number of conclusions can be drawn from the discussion in this article. First, the European Commission should generally refrain from regarding pay for delay settlements as restrictions by object, as their anticompetitive potential is less evident than in the United States, where a per se approach has been rejected. Secondly, the European Commission should not shy away from an effects-based approach. Similar to the guidance provided for the lower courts by the US Supreme Court in FTC v Actavis, the "structured effects based" test proposed by this article avoids an examination of the validity of the underlying patent without dis-incentivising general patent settlements in the pharmaceutical sector. In addition, the proposed test takes into consideration the described regulatory differences and only regards pay for delay settlements as anticompetitive if, based on the market structure, they have the actual potential to cause anticompetitive foreclosure. In more general policy terms, and even more importantly, this approach adjusts the balance between the aims of competition policy and exercise of intellectual property rights for the European pharmaceutical sector.
Pharmaceutical innovation is of utmost importance and should not be jeopardise by an overinterventionist application of competition law. Yet, at the same time, competition law and policy needs to ensure that the pharmaceutical market is competitive to make drugs affordable for as many patients as possible.
Furthermore the proposed test enhances legal certainty and does not require any legislative change. Legal certainty is enhanced as the test circumvents the most contentious and problematic issue -the probabilistic nature of patents and the need to determine their validity as part of the antitrust inquiry. Instead, the proposed test is a cost-based analysis into the economic gains received by the generic company as part of the pay for delay settlement.
This test is beneficial for the competition authority, who should be comfortable in administering a cost-based analysis, as well as for the brand and generic company, because the test offers a brighter line than a potential inquiry into the validity of the underlying patent, whose outcome is often difficult to predict.
The applicability of the proposed test is also provided under the current European competition law regime. The EU courts' effects-based approach in Delimitis can be regarded as a structured inquiry into anticompetitive effects. The proposed test is therefore to be seen as an extension to the rationale of Delimitis. The EU courts have also previously recognised, in relation to information exchange in RPM cases, that certain proxies might be used as evidence of effects. A truncated effects-based analysis is therefore not unheard of. The proposed test combines these two features. The European Commission should thus be able to issue guidelines for the pharmaceutical sector that set out the approach to pay for delay settlements and outline the facts considered in such an analysis.
